---

---

UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549

FORM 10-Q

|ý                                                       |  | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
|------------------------------------------------------- |  | ---------------------------------------------------------------------------------------
|For the Quarterly Period Ended September 30, 2002
  
OR
|o                                                       |  | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE EXCHANGE ACT OF 1934          
|For the Transition Period from            to           

Commission
file number 0-21321

CYMER, INC.(Exact name of registrant as specified in its charter)

|Nevada(State or other jurisdiction of
incorporation or organization) |  | 33-0175463(I.R.S. Employer Identification No.)
|-------------------------------------------------------------------- |  | ----------------------------------------------

|16750 Via Del Campo Court, San Diego, CA(Address of principal executive offices) |  | 92127(Zip Code)
|-------------------------------------------------------------------------------- |  | ---------------

Registrant's
telephone number, including area code:(858) 385-7300

Former
name, former address and former fiscal year, if changed since last report.
        N/A

Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes
ý No o

The
number of shares of Common Stock, with $0.001 par value, outstanding on November 8, 2002 was 34,123,541.

---

---

---



CYMER, INC.    FORM 10-Q    For the Quarter Ended September 30, 2002    INDEX

|               |  |                                                                                                       |  | Page
|-------------- |  | ----------------------------------------------------------------------------------------------------- |  | ----
|PART I.        |  | FINANCIAL INFORMATION                                                                                 |  |     
|ITEM 1.        |  | Consolidated Financial Statements (unaudited)                                                         |  |     
|               |  | Consolidated Balance Sheets as of December 31, 2001 and September 30, 2002                            |  | 3   
|               |  | Consolidated Statements of Operations for the three and nine months ended September 30, 2001 and 2002 |  | 4   
|               |  | Consolidated Statements of Cash Flows for the nine months ended September 30, 2001 and 2002           |  | 5   
|               |  | Notes to Consolidated Financial Statements                                                            |  | 6   
|ITEM 2.        |  | Management's Discussion and Analysis of Financial Condition and Results of Operations                 |  | 13  
|ITEM 3.        |  | Quantitative and Qualitative Disclosures About Market Risk                                            |  | 34  
|ITEM 4.        |  | Controls and Procedures                                                                               |  | 35  
|PART II.       |  | OTHER INFORMATION                                                                                     |  |     
|ITEM 1.        |  | Legal Proceedings                                                                                     |  | 36  
|ITEM 2.        |  | Changes in Securities and Use of Proceeds                                                             |  | 36  
|ITEM 3.        |  | Defaults upon Senior Securities                                                                       |  | 36  
|ITEM 4.        |  | Submission of Matters to a Vote of Security Holders                                                   |  | 36  
|ITEM 5.        |  | Other Information                                                                                     |  | 36  
|ITEM 6.        |  | Exhibits and Reports on Form 8-K                                                                      |  | 36  
|SIGNATURE PAGE |  | 37                                                                                                   
|CERTIFICATIONS |  | 38                                                                                                   

2

---



PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements

CYMER, INC.    CONSOLIDATED BALANCE SHEETS (UNAUDITED)  (In thousands, except share data)

|                                           |                                                                                                                                                                                | December 31,
2001 |                            | September 30,
2002 |  
|------------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ----------------- | -------------------------- | ------------------ | -
|ASSETS                                     |                                                                                                                                                                                |                   |                            |                    |  
|CURRENT ASSETS:                            |                                                                                                                                                                                |                   |                            |                    |  
|                                           | Cash and cash equivalents                                                                                                                                                      |                   | $                          | 111,195            |  
|                                           | Short-term investments                                                                                                                                                         |                   |                            | 82,988             |  
|                                           | Accounts receivablenet                                                                                                                                                        |                   |                            | 50,056             |  
|                                           | Foreign currency forward exchange contracts                                                                                                                                    |                   |                            | 3,197              |  
|                                           | Inventories                                                                                                                                                                    |                   |                            | 61,784             |  
|                                           | Deferred income taxescurrent                                                                                                                                                  |                   |                            | 16,935             |  
|                                           | Income taxes receivable                                                                                                                                                        |                   |                            | 3,039              |  
|                                           | Prepaid expenses and other assets                                                                                                                                              |                   |                            | 3,308              |  
|                                           |                                                                                                                                                                                |                   |                            |                    |  
|                                           |                                                                                                                                                                                |                   | Total current assets       |                    |  
|PROPERTY AND EQUIPMENTNET                 |                                                                                                                                                                                |                   | 90,419                     |                    |  
|LONG-TERM INVESTMENTS                      |                                                                                                                                                                                |                   | 23,015                     |                    |  
|DEFERRED INCOME TAXESNON-CURRENT          |                                                                                                                                                                                |                   | 12,269                     |                    |  
|GOODWILLNET                               |                                                                                                                                                                                |                   | 9,791                      |                    |  
|INTANGIBLE ASSETSNET                      |                                                                                                                                                                                |                   | 10,633                     |                    |  
|OTHER ASSETS                               |                                                                                                                                                                                |                   | 4,717                      |                    |  
|                                           |                                                                                                                                                                                |                   |                            |                    |  
|TOTAL ASSETS                               |                                                                                                                                                                                | $                 | 483,346                    |                    | $
|                                           |                                                                                                                                                                                |                   |                            |                    |  
|LIABILITIES AND STOCKHOLDERS' EQUITY       |                                                                                                                                                                                |                   |                            |                    |  
|CURRENT LIABILITIES:                       |                                                                                                                                                                                |                   |                            |                    |  
|                                           | Accounts payable                                                                                                                                                               |                   | $                          | 15,729             |  
|                                           | Accrued and other current liabilities                                                                                                                                          |                   |                            | 51,270             |  
|                                           | Foreign currency forward exchange contracts                                                                                                                                    |                   |                            |                   |  
|                                           | Revolving loan                                                                                                                                                                 |                   |                            | 7,652              |  
|                                           |                                                                                                                                                                                |                   |                            |                    |  
|                                           |                                                                                                                                                                                |                   | Total current liabilities  |                    |  
|                                           |                                                                                                                                                                                |                   |                            |                    |  
|CONVERTIBLE SUBORDINATED NOTES             |                                                                                                                                                                                |                   | 147,335                    |                    |  
|OTHER LIABILITIES                          |                                                                                                                                                                                |                   | 4,437                      |                    |  
|MINORITY INTEREST                          |                                                                                                                                                                                |                   | 2,109                      |                    |  
|COMMITMENTS AND CONTINGENCIES              |                                                                                                                                                                                |                   |                            |                    |  
|STOCKHOLDERS' EQUITY:                      |                                                                                                                                                                                |                   |                            |                    |  
|                                           | Preferred stockauthorized 5,000,000 shares; $.001 par value, no shares issued or outstanding                                                                                  |                   |                            |                   |  
|                                           | Common stockauthorized 100,000,000 shares; $.001 par value, issued and outstanding 30,848,000 and 33,986,000 shares at December 31, 2001 and September 30, 2002, respectively |                   |                            | 31                 |  
|                                           | Additional paid-in capital                                                                                                                                                     |                   |                            | 184,794            |  
|                                           | Treasury stock, at cost (2,000,000 common shares)                                                                                                                              |                   |                            | (24,871            | )
|                                           | Unearned compensation                                                                                                                                                          |                   |                            | (3,468             | )
|                                           | Accumulated other comprehensive loss                                                                                                                                           |                   |                            | (3,662             | )
|                                           | Retained earnings                                                                                                                                                              |                   |                            | 101,990            |  
|                                           |                                                                                                                                                                                |                   |                            |                    |  
|                                           |                                                                                                                                                                                |                   | Total stockholders' equity |                    |  
|                                           |                                                                                                                                                                                |                   |                            |                    |  
|TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |                                                                                                                                                                                | $                 | 483,346                    |                    | $
|                                           |                                                                                                                                                                                |                   |                            |                    |  

See Notes to Unaudited Consolidated Financial Statements.

3

---

CYMER, INC.        CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)  (In thousands, except per share data)

|                                                                                      |                                                                         | For the three months
ended September 30, |                          | For the nine months
ended September 30, |  
|------------------------------------------------------------------------------------- | ----------------------------------------------------------------------- | ---------------------------------------- | ------------------------ | --------------------------------------- | -
|
|REVENUES:                                                                             |                                                                         |                                          |                          |                                         |  
|                                                                                      | Product sales                                                           |                                          | $                        | 52,521                                  |  
|                                                                                      | Other                                                                   |                                          |                          | 514                                     |  
|                                                                                      |                                                                         |                                          |                          |                                         |  
|                                                                                      |                                                                         |                                          | Total revenues           |                                         |  
|                                                                                      |                                                                         |                                          |                          |                                         |  
|COSTS AND EXPENSES:                                                                   |                                                                         |                                          |                          |                                         |  
|                                                                                      | Cost of product sales                                                   |                                          |                          | 32,400                                  |  
|                                                                                      | Research and development                                                |                                          |                          | 13,790                                  |  
|                                                                                      | Sales and marketing                                                     |                                          |                          | 3,989                                   |  
|                                                                                      | General and administrative                                              |                                          |                          | 4,240                                   |  
|                                                                                      | Amortization of goodwill and intangible assets                          |                                          |                          | 894                                     |  
|                                                                                      | Purchased in-process research and development                           |                                          |                          |                                        |  
|                                                                                      |                                                                         |                                          |                          |                                         |  
|                                                                                      |                                                                         |                                          | Total costs and expenses |                                         |  
|                                                                                      |                                                                         |                                          |                          |                                         |  
|OPERATING INCOME (LOSS)                                                               |                                                                         |                                          | (2,278                   | )                                       |  
|                                                                                      |                                                                         |                                          |                          |                                         |  
|OTHER INCOME (EXPENSE):                                                               |                                                                         |                                          |                          |                                         |  
|                                                                                      | Foreign currency exchange gain (loss)net                               |                                          |                          | (358                                    | )
|                                                                                      | Interest and other income                                               |                                          |                          | 1,782                                   |  
|                                                                                      | Interest and other expense                                              |                                          |                          | (2,690                                  | )
|                                                                                      |                                                                         |                                          |                          |                                         |  
|                                                                                      |                                                                         |                                          | Total other expensenet  |                                         |  
|                                                                                      |                                                                         |                                          |                          |                                         |  
|INCOME (LOSS) BEFORE INCOME TAX PROVISION (BENEFIT) AND MINORITY INTEREST             |                                                                         |                                          | (3,544                   | )                                       |  
|INCOME TAX (BENEFIT) PROVISION                                                        |                                                                         |                                          | (886                     | )                                       |  
|MINORITY INTEREST                                                                     |                                                                         |                                          | (194                     | )                                       |  
|                                                                                      |                                                                         |                                          |                          |                                         |  
|INCOME (LOSS) BEFORE EXTRAORDINARY ITEM AND CUMULATIVE CHANGE IN ACCOUNTING PRINCIPLE |                                                                         |                                          | (2,852                   | )                                       |  
|                                                                                      | Extraordinary gain (loss) on debt extinguishment                        |                                          |                          | 70                                      |  
|                                                                                      | Cumulative change in accounting principle                               |                                          |                          |                                        |  
|                                                                                      |                                                                         |                                          |                          |                                         |  
|NET INCOME (LOSS)                                                                     |                                                                         | $                                        | (2,782                   | )                                       | $
|                                                                                      |                                                                         |                                          |                          |                                         |  
|EARNINGS (LOSS) PER SHARE:                                                            |                                                                         |                                          |                          |                                         |  
|Basic earnings (loss) per share:                                                      |                                                                         |                                          |                          |                                         |  
|                                                                                      | Before extraordinary item and cumulative change in accounting principle |                                          | $                        | (0.09                                   | )
|                                                                                      | Extraordinary gain (loss) on debt extinguishment                        |                                          |                          |                                        |  
|                                                                                      | Cumulative change in accounting principle                               |                                          |                          |                                        |  
|                                                                                      |                                                                         |                                          |                          |                                         |  
|                                                                                      | Basic earnings (loss) per share                                         |                                          | $                        | (0.09                                   | )
|                                                                                      |                                                                         |                                          |                          |                                         |  
|                                                                                      | Weighted average common shares outstanding                              |                                          |                          | 30,657                                  |  
|                                                                                      |                                                                         |                                          |                          |                                         |  
|Diluted earnings (loss) per share:                                                    |                                                                         |                                          |                          |                                         |  
|                                                                                      | Before extraordinary item and cumulative change in accounting principle |                                          | $                        | (0.09                                   | )
|                                                                                      | Extraordinary gain (loss) on debt extinguishment                        |                                          |                          |                                        |  
|                                                                                      | Cumulative change in accounting principle                               |                                          |                          |                                        |  
|                                                                                      |                                                                         |                                          |                          |                                         |  
|                                                                                      | Diluted earnings (loss) per share                                       |                                          | $                        | (0.09                                   | )
|                                                                                      |                                                                         |                                          |                          |                                         |  
|                                                                                      | Weighted average common and common equivalent shares outstanding        |                                          |                          | 30,657                                  |  
|                                                                                      |                                                                         |                                          |                          |                                         |  

See Notes to Unaudited Consolidated Financial Statements.

4

---



CYMER, INC.        CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)  (In thousands)

|                                                                        |                                                                                   | For the nine months ended
September 30,                      |                                                    
|----------------------------------------------------------------------- | --------------------------------------------------------------------------------- | ------------------------------------------------------------ | ---------------------------------------------------
|
|OPERATING ACTIVITIES:                                                   |                                                                                   |                                                              |                                                    
|                                                                        | Net income                                                                        |                                                              | $                                                  
|                                                                        | Adjustments to reconcile net income to net cash provided by operating activities: |                                                              |                                                    
|                                                                        |                                                                                   | Cumulative change in accounting principle                    |                                                    
|                                                                        |                                                                                   | Extraordinary (gain) loss on debt extinguishment             |                                                    
|                                                                        |                                                                                   | Depreciation and amortization                                |                                                    
|                                                                        |                                                                                   | Amortization of unearned compensation                        |                                                    
|                                                                        |                                                                                   | Minority interest                                            |                                                    
|                                                                        |                                                                                   | Purchased in-process research and development                |                                                    
|                                                                        |                                                                                   | Provision for deferred income taxes                          |                                                    
|                                                                        |                                                                                   | Loss on disposal and impairment of property and equipment    |                                                    
|                                                                        |                                                                                   | Change in assets and liabilitiesnet of acquisition in 2001: |                                                    
|                                                                        |                                                                                   |                                                              | Accounts receivable, net                           
|                                                                        |                                                                                   |                                                              | Income taxes receivable                            
|                                                                        |                                                                                   |                                                              | Foreign currency forward exchange contracts        
|                                                                        |                                                                                   |                                                              | Inventories                                        
|                                                                        |                                                                                   |                                                              | Prepaid expenses and other assets                  
|                                                                        |                                                                                   |                                                              | Accounts payable                                   
|                                                                        |                                                                                   |                                                              | Accrued and other liabilities                      
|                                                                        |                                                                                   |                                                              | Income taxes payable                               
|                                                                        |                                                                                   |                                                              |                                                    
|                                                                        |                                                                                   |                                                              | Net cash provided by operating activities          
|                                                                        |                                                                                   |                                                              |                                                    
|INVESTING ACTIVITIES:                                                   |                                                                                   |                                                              |                                                    
|                                                                        | Acquisition of property and equipment                                             |                                                              |                                                    
|                                                                        | Purchases of investments                                                          |                                                              |                                                    
|                                                                        | Proceeds from sold or matured investments                                         |                                                              |                                                    
|                                                                        | Acquisition of Active Control eXperts, Inc., net of cash acquired                 |                                                              |                                                    
|                                                                        | Acquisition of patents                                                            |                                                              |                                                    
|                                                                        | Acquisition of minority interest                                                  |                                                              |                                                    
|                                                                        |                                                                                   |                                                              |                                                    
|                                                                        |                                                                                   |                                                              | Net cash used in investing activities              
|                                                                        |                                                                                   |                                                              |                                                    
|FINANCING ACTIVITIES:                                                   |                                                                                   |                                                              |                                                    
|                                                                        | Net borrowings under revolving loan and security agreements                       |                                                              |                                                    
|                                                                        | Proceeds from issuance of common stock                                            |                                                              |                                                    
|                                                                        | Redemption of convertible subordinated notes                                      |                                                              |                                                    
|                                                                        | Issuance of convertible subordinated notes                                        |                                                              |                                                    
|                                                                        | Offering costs from issuance of convertible subordinated notes                    |                                                              |                                                    
|                                                                        | Minority interest investment in subsidiary                                        |                                                              |                                                    
|                                                                        | Payments on capital lease obligations                                             |                                                              |                                                    
|                                                                        |                                                                                   |                                                              |                                                    
|                                                                        |                                                                                   |                                                              | Net cash provided by (used in) financing activities
|                                                                        |                                                                                   |                                                              |                                                    
|EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS            |                                                                                   |                                                              | (5,750                                             
|                                                                        |                                                                                   |                                                              |                                                    
|NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                    |                                                                                   |                                                              | (6,625                                             
|CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                        |                                                                                   |                                                              | 79,678                                             
|                                                                        |                                                                                   |                                                              |                                                    
|CASH AND CASH EQUIVALENTS AT END OF PERIOD                              |                                                                                   | $                                                            | 73,053                                             
|                                                                        |                                                                                   |                                                              |                                                    
|SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:                       |                                                                                   |                                                              |                                                    
|                                                                        | Interest paid                                                                     |                                                              | $                                                  
|                                                                        |                                                                                   |                                                              |                                                    
|                                                                        | Income taxes paid, net                                                            |                                                              | $                                                  
|                                                                        |                                                                                   |                                                              |                                                    
|SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: |                                                                                   |                                                              |                                                    
|                                                                        | Warrants issued for acquisition of patents                                        |                                                              | $                                                  
|                                                                        |                                                                                   |                                                              |                                                    
|                                                                        | Stock and stock options issued in acquisition of Active Control eXperts, Inc.     |                                                              | $                                                  
|                                                                        |                                                                                   |                                                              |                                                    
|                                                                        | Conversion of subordinated notes to equity                                        |                                                              |                                                    
|                                                                        |                                                                                   |                                                              |                                                    

See Notes to Unaudited Consolidated Financial Statements.

5

---



CYMER, INC.    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS    Three and Nine Months Ended September 30, 2002  (Unaudited)

1.    BASIS OF PRESENTATION

The accompanying consolidated financial information has been prepared by Cymer, Inc., and its wholly-owned and majority-owned subsidiaries (collectively,
"Cymer"), without audit, in accordance with the instructions to Form 10-Q and therefore does not include all information and footnotes necessary for a fair presentation of financial
position, results of operations and cash flows in accordance with accounting principles generally accepted in the United States of America.

Principles of ConsolidationThe consolidated financial statements include the accounts of Cymer, Inc., its wholly-owned
subsidiariesCymer Japan, Inc. ("Cymer Japan"), Cymer Singapore Pte Ltd. ("Cymer Singapore"), Cymer B.V. in the Netherlands ("Cymer B.V."), Cymer Southeast Asia, Inc.,
in Taiwan ("Cymer SEA"), Cymer Cambridge (formerly known as Active Control eXperts, Inc. or ACX), and its majority-owned subsidiary, Cymer Korea, Inc. ("Cymer Korea"). Cymer, Inc. owns
75% of Cymer Korea. Cymer sells its excimer laser light sources in Japan primarily through Cymer Japan. Cymer Korea, Cymer SEA, Cymer Singapore and Cymer B.V. are field service offices for customers
in those respective regions. All significant intercompany balances have been eliminated in consolidation.

Accounting EstimatesThe preparation of financial statements in conformity with accounting principles generally accepted in
the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.

Unaudited Interim Financial DataIn the opinion of management, the unaudited consolidated financial statements for the interim
periods presented reflect all adjustments, consisting only of normal recurring
accruals, necessary for a fair presentation of the financial position and results of operations as of and for such periods indicated. These consolidated financial statements and notes hereto should be
read in conjunction with the consolidated financial statements and notes thereto included in Cymer's Annual Report on Form 10-K for the year ended December 31, 2001. Results
for the interim periods presented herein are not necessarily indicative of results which may be reported for any other interim period or for the entire fiscal year.

ReclassificationsCertain amounts in the prior year consolidated financial statements have been reclassified to conform to
current period presentation.

2.    EARNINGS PER SHARE

Earnings Per ShareBasic earnings per share Three months ended Nine months ended ("EPS") excludes dilution and is computed by
dividing net income or loss attributable to common stockholders by the weighted-average of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if
securities or other contracts to issue common stock (convertible subordinated notes, warrants to purchase common stock and common stock options using the treasury

6

---

stock method) were exercised or converted into common stock. Potential common shares in the diluted EPS computation are excluded in loss periods as their effect would be anti-dilutive.

Three months ended
September 30,

Nine months ended
September 30,2001

2002

2001

2002(In thousands)Basic weighted average common shares outstanding

30,657

33,983

30,377

33,047Effect of dilutive securities:Warrants





15

29Options



606

693

1,482Diluted weighted average common and potential common shares outstanding

30,657

34,589

31,085

34,558


For
the three months ended September 30, 2001 and 2002, weighted average options and warrants to purchase 4,170,000 and 4,401,000 shares of common stock, respectively, were
outstanding but not included in the computation of diluted earnings per share as their effect was anti-dilutive. In addition, for the three months ended September 30, 2001 and 2002,
weighted average common shares attributable to convertible subordinated notes of 3,145,000 and 5,000,000, respectively, were not included in the calculation of diluted earnings per share as their
effect was also anti-dilutive.

For
the nine months ended September 30, 2001 and 2002, weighted average options and warrants to purchase 3,437,000 and 2,375,000 shares of common stock, respectively, were
outstanding but not included in the computation of diluted earnings per share as their effect was anti-dilutive. In addition, for the nine months ended September 30, 2001 and 2002,
weighted average common shares attributable to convertible subordinated notes of 3,473,000 and 5,103,000, respectively, were not included in the calculation of diluted earnings per share as their
effect was anti-dilutive.

3.    ACQUISITION

On February 13, 2001, Cymer acquired the Cambridge, Massachusetts based company now known as Cymer Cambridge in an all-stock transaction that
totaled approximately $24.8 million. Had this

7

---

company been acquired on January 1, 2001, Cymer's net income would have been as follows (in thousands, except per share data):

Nine months ended
September 30, 2001Reported net income

$
10,352Adjustments:Amortization of goodwill and intangible assets


(429
)Incremental net loss


(475
)Tax effect


226Total


(678
)Adjusted net income

$
9,674Basic earnings per share:As reported

$
0.34As adjusted

$
0.32Diluted earnings per share:As reported

$
0.33As adjusted

$
0.31


4.    BALANCE SHEET DETAILS

December 31,
2001

September 30,
2002(in thousands)INVENTORIES:Raw materials

$
26,294

$
34,300Work-in-progress


22,211


32,502Finished goods


26,807


40,585Allowance for excess and obsolete inventory


(13,528
)

(14,523
)Total

$
61,784

$
92,864ACCRUED AND OTHER LIABILITIES:Warranty and installation

$
27,908

$
31,128Payroll and payroll related


6,628


6,868Interest


10,397


1,094Other


6,337


8,930Total

$
51,270

$
48,020


5.    REPORTING COMPREHENSIVE INCOME

Comprehensive income includes net income, effective unrealized gains and losses on foreign currency forward exchange contracts, foreign currency translation
adjustments, and unrealized gains and losses on available-for-sale securities, which are recorded as short-term and long-term investments in the
accompanying consolidated balance sheet.

8

---

The
following table summarizes the change in each component of accumulated other comprehensive loss for the nine months ended September 30, 2002 (in thousands):

|                   |  |                   |  | Translation
adjustment,
net of tax |        | Total unrealized
gains on
available-for-sale
investments,
net of tax |   | Total unrealized
gains (losses) on
foreign currency
forward exchange
contracts, net of tax |  | Accumulated
other
comprehensive
loss |       
|------------------ |  | ----------------- |  | ---------------------------------- | ------ | -------------------------------------------------------------------- | - | ------------------------------------------------------------------------------------------ |  | ------------------------------------ | ------
|December 31, 2001  |  | Balance           |  | $                                  | (5,407 | )                                                                    | $ | 376                                                                                        |  | $                                    | 1,369 
|                   |  | Period net change |  |                                    | (276   | )                                                                    |   | 1,580                                                                                      |  |                                      | (1,813
|                   |  |                   |  |                                    |        |                                                                      |   |                                                                                            |  |                                      |       
|September 30, 2002 |  | Balance           |  | $                                  | (5,683 | )                                                                    | $ | 1,956                                                                                      |  | $                                    | (444  
|                   |  |                   |  |                                    |        |                                                                      |   |                                                                                            |  |                                      |       

6.    ADOPTION OF SFAS NO. 142

Cymer adopted Statement of Financial Accounting Standards No. 142 ("SFAS 142"), "Goodwill and Other Intangible Assets", on January 1, 2002.
SFAS 142 supercedes Accounting Principles Board Opinion No. 17, "Intangible Assets", and discontinues the amortization of goodwill and intangible assets with indefinite useful lives
associated with previous purchase business combinations. In addition, SFAS 142 includes provisions regarding the reclassification between goodwill and identifiable intangible assets in
accordance with the new definition of intangible assets set forth in Statement of Financial Accounting Standards No. 141 ("SFAS 141"), "Business Combinations", the reassessment of the
useful lives of existing intangible assets, and the annual testing for impairment of existing goodwill and other intangible assets with indefinite lives.

In
accordance with SFAS 142, beginning January 1, 2002, Cymer no longer amortizes goodwill and intangible assets with indefinite lives. Instead, Cymer will review these
assets periodically for impairment in accordance with the provisions of SFAS 142. As of June 30, 2002, Cymer completed its implementation of SFAS 142 and conducted the required
transitional impairment tests. Cymer determined that it has one reporting unit and that this single reporting unit is the entire company, or Cymer, Inc. This conclusion was reached due to the
integrated nature of the operations of Cymer, Inc. and its subsidiaries and the lack of differing economic characteristics between them. Cymer conducted the first step of the transitional
impairment test using this one reporting unit and concluded that no impairment of goodwill existed as of January 1, 2002.

Cymer
did not identify any amounts that were required to be reclassified out of previously reported goodwill in accordance with the new definition of intangible assets under
SFAS 141. In accordance with the provisions of SFAS 142, the assembled workforce intangible asset was reclassified to goodwill as of January 1, 2002. Existing technology
associated with Cymer's acquisition of ACX continues to be amortized over its estimated useful life of four years using the straight-line method. Cymer made no changes to its estimates of
the useful lives of its amortizable intangible assets in connection with the adoption of SFAS 142.

9

---

Components
of intangible assets acquired in prior purchase business combinations were as follows (in thousands):

|                               |                                      | December 31, 2001 |        | September 30, 2002
|------------------------------ | ------------------------------------ | ----------------- | ------ | ------------------
|
|Amortized intangible assets:   |                                      |                   |        |                   
|                               | Existing technology
ACX acquisition |                   | $      | 640               
|                               |                                      |                   |        |                   
|Unamortized intangible assets: |                                      |                   |        |                   
|                               | Goodwill                             |                   | $      | 12,734            
|                               | Assembled workforce
ACX acquisition |                   |        | 790               
|                               |                                      |                   |        |                   
|                               |                                      | $                 | 13,524 |                   
|                               |                                      |                   |        |                   

The above table only includes intangible assets associated with prior purchase business combinations. Also included in intangible
assetsnet on the accompanying balance sheets are amounts associated with patents which were acquired in 2001. As of December 31, 2001 and September 30, 2002, the net
carrying amount of these patents was $9.5 million and $8.5 million, respectively.

Aggregate
amortization expense was $2,253,000 for the nine months ended September 30, 2001 and $120,000 for the nine months ended September 30, 2002. As of
September 30, 2002, future estimated amortization expense is expected to be as follows (in thousands):

Future AmortizationThree months ending December 31, 2002

$
40Year ending December 31, 2003

$
160Year ending December 31, 2004

$
160Year ending December 31, 2005

$
20


Income
before extraordinary item and cumulative change in accounting principle, net income and earnings per share on a pro forma basis, excluding goodwill and intangible asset
amortization expense

10

---

related to intangibles no longer amortized, would have been as follows if SFAS 142 had been adopted on January 1, 2001 (in thousands, except per share data):

|                                                                                               |                                                                                     | Three months ended
September 30, |        | Nine months ended
September 30,
|---------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------- | -------------------------------- | ------ | -------------------------------
|
|Reported income (loss) before extraordinary item and cumulative change in accounting principle |                                                                                     | $                                | (2,852 | )                              
|                                                                                               |                                                                                     |                                  |        |                                
|Reported net income (loss)                                                                     |                                                                                     | $                                | (2,782 | )                              
|                                                                                               |                                                                                     |                                  |        |                                
|Adjustments:                                                                                   |                                                                                     |                                  |        |                                
|                                                                                               | Amortization of goodwill and intangible assets                                      |                                  |        | 854                            
|                                                                                               | Tax effect                                                                          |                                  |        | (214                           
|                                                                                               |                                                                                     |                                  |        |                                
|                                                                                               |                                                                                     |                                  | 640    |                                
|                                                                                               |                                                                                     |                                  |        |                                
|Adjusted income (loss) before extraordinary item and cumulative change in accounting principle |                                                                                     | $                                | (2,212 | )                              
|                                                                                               |                                                                                     |                                  |        |                                
|Adjusted net income                                                                            |                                                                                     | $                                | (2,142 | )                              
|                                                                                               |                                                                                     |                                  |        |                                
|Basic earnings (loss) per share:                                                               |                                                                                     |                                  |        |                                
|                                                                                               | As reportedbefore extraordinary item and cumulative change in accounting principle |                                  | $      | (0.09                          
|                                                                                               | As adjustedbefore extraordinary item and cumulative change in accounting principle |                                  | $      | (0.07                          
|                                                                                               | As reportednet income (loss)                                                       |                                  | $      | (0.09                          
|                                                                                               | As adjustednet income (loss)                                                       |                                  | $      | (0.07                          
|Diluted earnings (loss) per share:                                                             |                                                                                     |                                  |        |                                
|                                                                                               | As reportedbefore extraordinary item and cumulative change in accounting principle |                                  | $      | (0.09                          
|                                                                                               | As adjustedbefore extraordinary item and cumulative change in accounting principle |                                  | $      | (0.07                          
|                                                                                               | As reportednet income (loss)                                                       |                                  | $      | (0.09                          
|                                                                                               | As adjustednet income (loss)                                                       |                                  | $      | (0.07                          

7.    CONVERTIBLE SUBORDINATED NOTES

In August 1997, Cymer issued $172.5 million aggregate principal amount in a private placement of notes. These 31/2% /
71/4% Step-Up Convertible Subordinated Notes ("1997 Notes") were due August 6, 2004 and were convertible at the option of the holder into shares of common stock of
Cymer. The conversion rate on the notes was 21.2766 shares per $1,000 principal amount.

These
1997 Notes were called for redemption on March 25, 2002. Immediately prior to the March 25, 2002 redemption date, holders of $109.3 million of the outstanding
principal amount converted their 1997 Notes into shares of Cymer common stock. As a result of these conversions, 2,325,542 shares of Cymer's common stock were issued to holders of the 1997 Notes.
Cymer used its 2,000,000 shares of treasury stock as part of the total 2,325,542 shares issued in the conversion. The remaining $38 million
of the outstanding principal amount of the 1997 Notes was redeemed. The redemption price was 104.111% of the principal amount of the 1997 Notes, plus accrued and unpaid interest to the redemption
date. The redemption resulted in an extraordinary loss on debt extinguishment of $163,000, net of tax.

11

---

In
February 2002, Cymer issued $250 million principal amount of unsecured 31/2% Convertible Subordinated Notes due February 15, 2009 ("2002 Notes").
Interest on the 2002 Notes is payable on February 15 and August 15 of each year, commencing August 15, 2002. The 2002 Notes are convertible into shares of Cymer's common stock at
a conversion rate of 20 shares per $1,000 principal amount subject to adjustment under certain conditions. Cymer may redeem the 2002 Notes on or after February 20, 2005, or earlier if the price
of its common stock reaches certain levels. The 2002 Notes are subordinated to Cymer's existing and future senior indebtedness and effectively subordinated to all indebtedness and other liabilities of
Cymer's subsidiaries. A portion of the net proceeds of this private placement were used to redeem the Company's outstanding 1997 Notes.

8.    MATERIAL AGREEMENT

In July 2002, Cymer entered into an agreement with a contractor for the construction of a 265,000 square foot building adjacent to its corporate
headquarters located in San Diego, California. This manufacturing and office facility will be completed in two phases, with phase one currently scheduled for completion by April 2003 and phase
two currently expected to be completed by November 2003. Cymer will self-finance the cost of the construction project, which is estimated to be approximately $50 million.

9.    CONTINGENCIES

Cymer's Japanese manufacturing partner and at least one of Cymer's Japanese customers have been notified that Cymer's light source systems in Japan may infringe
certain Japanese patents held by another Japanese company. Cymer has agreed to indemnify its Japanese manufacturing partner and its customers against patent infringement claims under certain
circumstances. Cymer believes, based upon the advice of qualified Japanese counsel, that Cymer's products do not infringe any valid claim of the asserted patents or that it is entitled to prior user
rights in Japan.

12

---



ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Statements in this quarterly report on Form 10-Q that are not strictly historical in nature are forward-looking
statements. These statements include, but are not limited to, references to manufacturing activities; expected product sales and development; service and support; research and development
expenditures; expected product development; expected international product sales, development and revenue; adequacy of capital resources and investments; effects of business cycles in the
semiconductor business; competitive positioning; and continuing relationships with third-party manufacturers for product manufacturing. These statements include, without limitation, statements
containing the words "believes," "anticipates," "expects," and words of similar import. These statements are only predictions based on current information and expectations and involve a number of
risks and uncertainties. The underlying information and expectations are likely to change over time. Actual events or results may differ materially from those projected in the forward-looking
statements due to various factors, including, but not limited to, those set forth in this Item 2 and under the caption "Risk Factors" and elsewhere in this quarterly report on
Form 10-Q.

The following discussion of the financial condition and results of operations of Cymer should be read in conjunction with Cymer's consolidated financial
statements and notes thereto included elsewhere in this quarterly report on Form 10-Q and its consolidated financial statements and notes thereto included in Cymer's annual report
on Form 10-K for the year ended December 31, 2001.

RESULTS OF OPERATIONS

The following table sets forth certain items in Cymer's consolidated statements of operations as a percentage of total revenues for the periods indicated:

|                                                                                      |                                                  | Three months ended
September 30, |                          | Nine months ended
September 30, |      
|------------------------------------------------------------------------------------- | ------------------------------------------------ | -------------------------------- | ------------------------ | ------------------------------- | -----
|
|Revenues:                                                                             |                                                  |                                  |                          |                                 |      
|                                                                                      | Product sales                                    |                                  | 99.0                     | %                               | 99.6 
|                                                                                      | Other                                            |                                  | 1.0                      |                                 | .4   
|                                                                                      |                                                  |                                  |                          |                                 |      
|                                                                                      |                                                  |                                  | Total revenues           |                                 | 100.0
|Cost and expenses:                                                                    |                                                  |                                  |                          |                                 |      
|                                                                                      | Cost of product sales                            |                                  | 61.1                     |                                 | 56.1 
|                                                                                      | Research and development                         |                                  | 26.0                     |                                 | 24.4 
|                                                                                      | Sales and marketing                              |                                  | 7.5                      |                                 | 5.3  
|                                                                                      | General and administrative                       |                                  | 8.0                      |                                 | 6.4  
|                                                                                      | Amortization of goodwill and intangible assets   |                                  | 1.7                      |                                 |     
|                                                                                      | Purchased in-process research and development    |                                  |                         |                                 |     
|                                                                                      |                                                  |                                  |                          |                                 |      
|                                                                                      |                                                  |                                  | Total costs and expenses |                                 | 104.3
|                                                                                      |                                                  |                                  |                          |                                 |      
|Operating income (loss)                                                               |                                                  | (4.3                             | )                        | 7.8                             |      
|Other expensenet                                                                     |                                                  | (2.4                             | )                        | (0.5                            | )    
|                                                                                      |                                                  |                                  |                          |                                 |      
|Income (loss) before income tax provision (benefit) and minority interest             |                                                  | (6.7                             | )                        | 7.3                             |      
|Income tax (benefit) provision                                                        |                                                  | (1.7                             | )                        | (0.8                            | )    
|Minority interest                                                                     |                                                  | (.4                              | )                        |                                |      
|                                                                                      |                                                  |                                  |                          |                                 |      
|Income (loss) before extraordinary item and cumulative change in accounting principle |                                                  | (5.4                             | )                        | 8.1                             |      
|                                                                                      | Extraordinary gain (loss) on debt extinguishment |                                  | ..1                      |                                 |     
|                                                                                      | Cumulative change in accounting principle        |                                  |                         |                                 |     
|                                                                                      |                                                  |                                  |                          |                                 |      
|Net income (loss)                                                                     |                                                  | (5.3                             | %)                       | 8.1                             | %    
|                                                                                      |                                                  |                                  |                          |                                 |      
|Gross margin on product sales                                                         |                                                  | 38.3                             | %                        | 43.7                            | %    
|                                                                                      |                                                  |                                  |                          |                                 |      

13

---

THREE MONTHS ENDED SEPTEMBER 30, 2001 AND 2002

Revenues.Cymer's revenues consist of product sales, which include sales of laser light source systems, consumable and spare
parts, upgrades, service, training, and software. Other revenues include revenue from funded development activities performed for customers and government contracts. Revenue from product sales is
generally recognized at the time of shipment, unless customer agreements contain inspection, acceptance or other conditions, in which case revenue is recognized at the time such conditions are
satisfied. Funded development contracts are accounted for on the percentage-of-completion method based on the relationship of costs incurred to total estimated costs, after
giving effect to estimates of costs to complete the development project. If milestones on funded development contracts require that specific results be achieved or reported by Cymer, revenue is not
recognized until that milestone is completed.

Product
sales increased 60% from $52.5 million for the three months ended September 30, 2001 to $84.2 million for the three months ended September 30, 2002,
primarily due to a 39% increase in the number of light source systems unit sales coupled with a higher average selling price ("ASP") per system. A total of 62 laser light source systems were sold in
the three months ended September 30, 2001
at an ASP of $572,000, compared to 86 systems sold in the three months ended September 30, 2002 at an ASP of $708,000. On a currency adjusted basis, the ASP for the three months ended
September 30, 2001 was $587,000 as compared to $679,000 for the three months ended September 30, 2002. This increase in currency adjusted ASP from period to period reflects increased
sales in 2002 of Cymer's Nanolith-7000 and ELS-7000 series products which have higher ASPs compared to the ELS-6000/6010 KrF series products sold in 2001. Sales of
consumable and spare parts and service products increased 32% from $15.6 million to $20.6 million for the three months ended September 30, 2001 and 2002, respectively. The
increase in this type of product sales was due to increased utilization of Cymer's deep ultraviolet ("DUV") laser light sources by chipmakers and an increased installed base in the three months ended
September 30, 2002. Revenues from funded development projects were $514,000 and $314,000 for the three months ended September 30, 2001 and 2002, respectively.

Cymer's
backlog at September 30, 2001 was $94.5 million as compared to $83.6 million at September 30, 2002. Bookings for the three months ended
September 30, 2001 and September 30, 2002 were $38.1 million and $55.2 million, respectively. The book to bill ratio for the three months ended September 30, 2001
was .78 as compared to .69 for the three months ended September 30, 2002. Cymer installed 82 light sources at chipmakers and other end-users during the third quarter of 2001 as
compared to 61 light sources installed during the third quarter of 2002.

Cymer's
sales are generated primarily by shipments to customers in Japan, the Netherlands, and the United States. Approximately 89% and 92% of Cymer's sales for the three months ended
September 30, 2001 and 2002, respectively, were derived from customers outside the United States. Cymer maintains a wholly-owned Japanese subsidiary which sells to Cymer's Japanese customers.
Revenues from Japanese customers, generated primarily by this subsidiary, accounted for 46% and 39% of revenues for the three months ended September 30, 2001 and 2002, respectively. The
activities of Cymer's Japanese subsidiary are limited to sales and service of products purchased by the subsidiary from the parent corporation. Cymer anticipates that international sales will continue
to account for a significant portion of its net sales.

Cost of Product Sales.Cost of product sales includes direct material and labor, warranty expenses, license fees, and
manufacturing and service overhead, and foreign exchange gains and losses on foreign currency forward exchange contracts associated with purchases of Cymer's products by its Japanese subsidiary for
resale under firm third-party sales commitments. In accordance with the provisions of Statement of Financial Accounting Standards No. 133 ("SFAS 133"), "Accounting for Derivative
Instruments and Hedging Activities," for those derivative instruments that do not qualify for hedge accounting, deferral of the gains or losses is not allowed and the gains and losses are recorded in
other

14

---

income (expense). Cymer adopted SFAS 133 on January 1, 2001, but did not qualify for hedge accounting until July 1, 2001. Accordingly, for contracts entered into prior to
July 1, 2001, Cymer recorded changes in the fair value of its foreign currency forward exchange contracts directly through earnings in other income (expense) in the period such changes occur.
For contracts entered into on or after July 1, 2001, Cymer defers effective changes in the fair value of its foreign currency forward exchange contracts into other comprehensive income (loss)
and subsequently reclassifies the effective changes to cost of product sales in the same period that the related sale is made to the third party.

Cost
of product sales increased 46% from $32.4 million for the three months ended September 30, 2001 to $47.4 million for the three months ended September 30,
2002 due primarily to the increase in product sales volume. The gross margin on these sales was 38.3% and 43.7% for the three months ended September 30, 2001 and September 30, 2002,
respectively. This improvement in gross margin was the result of increased production levels associated with increased product sales and inventory builds on a relatively flat level of manufacturing
expenses from period to period.

For
the three months ended September 30, 2001, only those foreign currency forward exchange contracts meeting the transition period requirements under SFAS 133 and
contracts entered into after July 1, 2001 were included in cost of product sales in the consolidated statements of income. For the three months ended September 30, 2002, Cymer qualified
for hedge accounting treatment under SFAS 133 and was able to record the net effect of gains or losses from foreign currency forward exchange contracts in cost of product sales in the
consolidated statements of income as the related sale to the third party was recognized. Cymer recognized a net loss in cost of sales on such contracts of $89,000 and $2.0 million for the three
months ended September 30, 2001 and 2002, respectively.

Research and Development.Research and development expenses include costs of internally-funded and externally-funded projects
as well as continuing research support expenses which primarily include employee and material costs, depreciation of equipment and other engineering related costs. Research and development expenses
increased 49% from $13.8 million for the three months ended September 30, 2001 to $20.6 million for the three months ended September 30, 2002, due primarily to Cymer's
increased investment in the development of higher value-added next generation products. During the third quarter of 2002, Cymer continued its investment in its newest product development effort, the
master oscillator power amplifier ("MOPA") platform, or XLA series. Cymer is scheduled to ship the first light source system that utilizes the MOPA platform, the XLA-100, in the first
quarter of 2003. Cymer also continued to invest during the quarter in extreme ultraviolet ("EUV") technology and the continuing engineering of the ELS-7000 and Nanolith-7000
products. As a percentage of total revenues, such expenses decreased from 26.0% to 24.4%, primarily due to the larger revenue base in 2002.

Sales and Marketing.Sales and marketing expenses include the expenses of the sales, marketing and customer support staffs
and other marketing expenses. Sales and marketing expenses increased 12% from $4.0 million for the three months ended September 30, 2001 to $4.5 million for the three months ended
September 30, 2002 due primarily to the level of cost reductions that occurred in 2001 as compared to 2002 in response to the downturn in the semiconductor industry. As a percentage of total
revenues, such expenses decreased from 7.5% to 5.3%, primarily due to the larger revenue base in 2002.

General and Administrative.General and administrative expenses consist primarily of management and administrative personnel
costs, professional services and administrative operating costs. General and administrative expenses increased 28% from $4.2 million for the three months ended September 30, 2001 to
$5.4 million for the three months ended September 30, 2002. This was primarily due to start-up costs associated with Cymer's new Korean manufacturing facility and increased
tax professional services. As a percentage of total revenues, such expenses decreased from 8.0% to 6.4%, primarily due to the larger revenue base in 2002.

15

---

Other ExpenseNet.Net other income (expense) consists primarily of interest income and expense and foreign
currency exchange gains and losses associated with fluctuations in the value of the Japanese yen against the United States dollar and gains and losses on foreign currency forward exchange contracts.
Net other expense totaled $1.3 million and $444,000 for the three months ended September 30, 2001 and 2002, respectively. The decrease in net other expense was primarily due to higher
interest income earned on Cymer's higher cash and investment balances during the third quarter of 2002. These increased cash and investment balances during the three months ended September 30,
2002 are due to the additional cash resulting from the private placement of the 2002 Notes, the call for redemption of the 1997 Notes and the conversion of a significant portion of the 1997 Notes
prior to redemption, all of which were completed during the first quarter of 2002. Interest expense was also lower due to the 3.5% interest rate on the 2002 Notes as compared to the blended 5.47%
interest rate on the 1997 Notes. Foreign currency exchange losses totaled $358,000, interest income totaled $1.8 million and interest expense totaled $2.7 million for the three months
ended September 30, 2001, compared to a foreign currency exchange losses of $542,000, interest income of $2.8 million and interest expense of $2.7 million for the three months
ended September 30, 2002.

Cymer's
results of operations are subject to fluctuations in the value of the Japanese yen against the United States dollar. Sales by Cymer to its Japanese subsidiary are denominated in
dollars, and sales by the subsidiary to customers in Japan are denominated in yen. Cymer's Japanese subsidiary manages its exposure to such fluctuations by entering into foreign currency forward
exchange contracts to hedge its cash flow exposure to Cymer. From January 1, 2001 through June 30, 2001, gains or losses resulting from the change in the value of contracts entered into
prior to July 1, 2001 were recorded as other income (expense) in the consolidated statements of income. Subsequent to June 30, 2001, gains or losses resulting from contracts entered into
after July 1, 2001 are initially recorded in other comprehensive income (loss). The net amount of unrealized effective gain or loss on the date the laser light source system is received by
Cymer's Japanese subsidiary is reclassified to cost of sales on the date that the laser light source is sold to the third party. Gains and losses resulting from foreign currency translation are
accumulated as a separate component of consolidated stockholders' equity.

Income Tax Provision.The tax benefit of $886,000 and $687,000 for the three months ended September 30, 2001 and 2002,
respectively, reflects an annual effective rate of 25% and 16%, respectively. The decrease in the annual effective tax rate during the three months ended September 30, 2002 from 27% to 16% is
primarily attributable to increased tax benefits associated with foreign sales and increased benefit from research credits for the year. The annual effective tax rates for both periods are less than
the U.S. statutory rate of 35% primarily as a result of permanent book/tax differences and tax credits.

NINE MONTHS ENDED SEPTEMBER 30, 2001 AND 2002

Revenues.Product sales increased 3% from $212.7 million for the nine months ended September 30, 2001 to
$218.7 million for the nine months ended September 30, 2002. This increase in sales was primarily due to increased ASPs, which was offset by lower light source systems unit sales from
period to period. During both the nine months ended September 30, 2001 and 2002, Cymer's sales levels were impacted by the downturn in the semiconductor industry. In the first nine months of
2001, Cymer's revenues and volumes dropped as the semiconductor industry first entered the downturn. In the first nine months of 2002, Cymer continued to have sales volumes indicative of a continued
downturn. A total of 280 laser light source systems were sold in the nine months ended September 30, 2001 at an ASP of $543,000, compared to 218 systems sold in the nine months ended
September 30, 2002 at an ASP of $717,000. On a currency adjusted basis, the ASP for the nine months ended September 30, 2001 was $558,000 as compared to $714,000 for the nine months
ended September 30, 2002. Although the total number of laser light source systems sold during the nine months ended September 30, 2002 was lower than that sold during the same nine month
period in 2001, the total

16

---

revenue generated from such systems sales during the first nine months of 2002 was higher than those in the first nine months of 2001. This is due to increased sales by Cymer of its newer model laser
light sources in 2002, particularly its Nanolith-7000 product and its ELS-7000 product. Sales of spares and consumables and service products were slightly higher in 2002 than
those in 2001. For the first nine months of 2001, Cymer had $55.1 million in such sales as compared to $57.5 million for the first nine months in 2002. Revenue from funded development
projects was $2.0 million and $1.5 million for the nine months ended September 30, 2001 and 2002, respectively.

Approximately
84% and 90% of Cymer's sales for the nine months ended September 30, 2001 and 2002, respectively, were derived from customers outside the United States. Revenues
from Japanese customers, generated primarily by Cymer's wholly-owned Japanese subsidiary, accounted for 44% and 41% of revenues for the nine months ended September 30, 2001 and 2002,
respectively.

Sales
to Cymer's three largest customers, ASM Lithography, Canon, and Nikon amounted to 29%, 18% and 29%, respectively, of total revenue for the nine months ended September 30,
2001 and 34%, 19% and 24%, respectively, of total revenue for the nine months ended September 30, 2002.

Cost of Product Sales.Cost of product sales decreased 1% from $119.0 million for the nine months ended
September 30, 2001 to $117.7 million for the nine months ended September 30, 2002 due primarily to decreased manufacturing expense levels and increased manufacturing efficiencies.
The gross margin on these sales was 44.1% and 46.2% for the nine months ended September 30, 2001 and September 30, 2002, respectively. The increase in gross margin in 2002 as compared to
2001 is primarily due to production activities and inventory levels from period to period. Although there were fewer light source system unit sales during the nine months ended September 30,
2002 as compared to the same period during 2001, production levels were much higher and ending inventory balances were increased in 2002.
For the nine months ended September 30, 2001, Cymer decreased its inventory balances by $17.1 million whereas it increased its inventory balances by $30.2 million for the nine months ended
September 30, 2002.

For
the nine months ended September 30, 2001, only those contracts meeting the transition period requirements under SFAS 133 were included in cost of product sales in the
consolidated statements of income. For the nine months ended September 30, 2002, Cymer qualified for hedge accounting treatment under SFAS 133 and was able to record the net effect of
gains or losses from foreign currency forward exchange contracts in cost of product sales in the consolidated statements of income as the related sale to the third party was recognized. Cymer
recognized net gains in cost of sales on such contracts of $2.3 million for the nine months ended September 30, 2001, as compared to a net loss of $438,000 for the nine months ended
September 30, 2002.

Research and Development.Research and development expenses increased 22% from $44.1 million for the nine months ended
September 30, 2001 to $53.6 million for the nine months ended September 30, 2002, due primarily to Cymer's increased investment in higher value-added next generation products.
During the nine months ended September 30, 2002, these development efforts included Cymer's continued investment in the MOPA platform, or XLA series, as well as continued investments in EUV and
continuing engineering of the ELS-7000 and Nanolith-7000 products. As a percentage of total revenues, September 30, 2001 and 2002 expenses increased from 20.5% to 24.3%,
respectively, due to increased spending.

Sales and Marketing.Sales and marketing expenses decreased 20% from $15.3 million for the nine months ended
September 30, 2001 to $12.3 million for the nine months ended September 30, 2002 due primarily to increased operational efficiencies as well as heightened cost controls as a
result of the continued downturn in the semiconductor industry. As a percentage of total revenues, such expenses decreased from 7.1% to 5.6% due to decreased spending.

17

---

General and Administrative.General and administrative expenses decreased 9% from $14.7 million for the nine months
ended September 30, 2001 to $13.5 million for the nine months ended September 30, 2002. This was due primarily to ongoing improvements in operational efficiencies and increased
cost controls in 2002 due to overall industry conditions. This was offset by start-up costs associated with Cymer's new manufacturing facility in Korea. As a percentage of total revenues,
such expenses decreased from 6.9% to 6.1% due to decreased spending.

Purchased In-Process Research and Development.Purchased in-process research and development expenses
consist of costs associated with the acquisition of ACX and its in-process research and development projects. The total amount of such expenses for the nine months ended
September 30, 2001 was $5.1 million. These expenses represented the fair value of ACX's development projects associated with the application of its technology to the semiconductor
market. As of the date of the acquisition, this
purchased in-process research and development was expensed because the application of this technology to the semiconductor market was at a stage of development that required further
research and development before reaching technological feasibility and commercial viability. There were no such expenses for the nine months ended September 30, 2002.

Other ExpenseNet.Net other expense totaled $326,000 and $1.7 million for the nine months ended
September 30, 2001 and 2002, respectively. The increase in net other expense was primarily due to the classification of gains associated with the change in value of foreign currency forward
exchange contracts per SFAS 133 in 2001. Since Cymer did not qualify for hedge accounting treatment under SFAS 133 until July 1, 2001, all such gains, except those meeting the
transitional period requirements, were recorded in the other income (expense) section of the consolidated statements of income. Cymer qualified for hedge accounting treatment during all of 2002 and
thus recorded gains associated with its foreign currency forward exchange contracts to cost of product sales in the same period that the related sale was made to the third party. The increase in
interest expense was primarily attributable to additional interest expense incurred during the nine months ended September 30, 2002 in connection with Cymer's private placement of the 2002
Notes in February 2002 and the redemption of its 1997 Notes in March 2002. This increase in expense was offset by an increase in interest income primarily attributable to increased
investment balances due to the additional cash generated from the 2002 Notes. Foreign currency exchange gains totaled $1.2 million, interest income totaled $6.7 million and interest
expense totaled $8.3 million for the nine months ended September 30, 2001, compared to a foreign currency exchange loss of $422,000, interest income of $7.4 million and interest
expense of $8.6 million for the nine months ended September 30, 2002.

Income Tax Provision.The tax provision of $3.5 million and $3.4 million for the nine months ended
September 30, 2001 and 2002, respectively, reflects an annual effective rate of 25% and 16%, respectively. The lower annual effective tax rate during the nine months ended September 30,
2002 compared to the same nine months in the previous year is primarily attributable to increased tax benefits associated with foreign sales and nondeductible amortization of goodwill and in-process
research and development associated with the ACX acquisition in 2001. The annual effective tax rates for both periods are less than the U.S. statutory rate of 35% primarily as a result of permanent
book/tax differences and tax credits.

LIQUIDITY AND CAPITAL RESOURCES

As of September 30, 2002, Cymer had approximately $168.1 million in cash and cash equivalents, $80.7 million in short-term
investments, $169.1 million in long-term investments, and $353.3 million in working capital.

In
August 1997, Cymer issued $172.5 million in aggregate principal amount in a private placement of notes. The 31/2% / 71/4%
Step-Up Convertible Subordinated Notes were due on August 6, 2004 and were convertible at the option of the holder into shares of common stock of Cymer. The conversion

18

---

rate on the 1997 Notes was 21.2766 shares per $1,000 principal amount. The 1997 Notes were called for redemption on March 25, 2002. Immediately prior to the March 25, 2002 redemption
date, holders of $109.3 million of the outstanding principal amount converted their 1997 Notes into shares of Cymer's common stock. As a result of these conversions, 2,325,542 shares of Cymer
common stock were issued to the note holders and the remaining $38.0 million of the outstanding principal amount of the 1997 Notes was redeemed.

In
February 2002, Cymer issued $250 million in aggregate principal amount in a private placement of notes. The 2002 Notes are due on February 15, 2009 with interest
payable semi-annually on February 15 and August 15 of each year at 31/2% per annum. The notes are convertible into shares of Cymer common stock at a conversion
rate of 20 shares per $1,000 principal amount. Cymer used a portion of the net proceeds from this private placement to redeem the 1997 Notes. The remaining proceeds will be used for Cymer's future
operating, investing and financing activities.

Net
cash provided by operating activities was approximately $40.9 million and $1.8 million for the nine months ended September 30, 2001 and 2002, respectively. The
decrease in cash provided by operating activities from period to period was primarily due to large increases in inventories and accounts receivable during 2002 which were partially offset by higher
net income, increases in accounts payable, accrued and other liabilities and income taxes receivable. The changes in accounts receivable and inventories were due to the start of the industry downturn
and decreased sales and bookings during the nine month period ending September 30, 2001, as compared to increased bookings and higher production levels during the nine months ended
September 30, 2002.

Net
cash used in investing activities was approximately $16.6 million and $166.0 million for the nine months ended September 30, 2001 and 2002, respectively. For the
nine months ended September 30, 2001, the cash provided by investing activities was primarily due to the timing of short-term and long-term investments maturing and
being reinvested during the period, offset by a $6.0 million payment made to acquire patents and the purchase of $16.8 million in capital equipment in support of normal business
activities during the period. The cash used in investing activities of $166.0 million during the nine months ended September 30, 2002 primarily reflects short-term and
long-term investments being made from the net proceeds resulting from the convertible subordinated note transactions in February and March 2002, and $24.5 million in capital
equipment purchases. Included in these capital purchases for 2002 are costs associated with Cymer's new spare parts refurbishment factory in Korea, which was completed in September 2002, and
costs associated with the construction of a new manufacturing and office facility adjacent to its corporate headquarters located in San Diego, California.

In
July 2002, Cymer entered into an agreement with a contractor for the construction of a 265,000 square foot building adjacent to the corporate headquarters. This manufacturing
and office facility will be completed in two phases, with phase one currently scheduled for completion by April 2003 and phase two currently expected to be completed by November 2003.
Cymer will self-fund the cost of the construction project, which is estimated to be approximately $50 million.

Net
cash used in financing activities was approximately $25.1 million for the nine months ended September 30, 2001 as compared to net cash provided by financing activities
of approximately
$221.0 million for the nine months ended September 30, 2002. The net cash used in financing activities for the nine months ended September 30, 2001 was attributable to the
repurchase of $24.9 million in outstanding 1997 Notes and an $8.7 million payment on Cymer's revolving loan during the period, offset by the receipt of $8.8 million upon issuance
of common stock due to employee stock option exercises. For the nine month period ended September 30, 2002, the $221.0 million provided by financing activities was primarily due to the
activity during the first quarter of 2002 on Cymer's convertible subordinated notes. The private placement of 2002 notes that Cymer completed in February 2002 resulted in net proceeds to the
company of approximately $242.1 million. Of these net

19

---

proceeds, Cymer used $39.6 million to redeem a portion of its outstanding 1997 Notes and to pay accrued interest and premiums due on those notes. In addition, Cymer received greater proceeds
from employee stock option exercises during the nine months ended September 30, 2002 as compared to September 30, 2001 due to increased options exercises attributable to higher market
valuations of Cymer's stock from period to period. The total proceeds from such employee stock option exercises were $8.8 million and $18.3 million during the nine months ended September 30,
2001 and 2002, respectively.

Since
its initial public offering and a secondary public offering, both in 1996, Cymer has funded its operations primarily from cash generated from operations, the proceeds of
convertible subordinated note offerings in August 1997 and February 2002, bank borrowings, and the proceeds from employee stock option exercises.

Cymer
requires substantial working capital to fund its business, particularly to finance inventories and accounts receivable and for capital expenditures. Cymer's future capital
requirements depend on many factors, including Cymer's manufacturing activity, the timing and extent of spending to support product development efforts, expansion of sales and marketing and field
service and support, competitive labor market compensation requirements, the timing of introductions of new products and enhancements to existing products, and the market acceptance of Cymer's
products. Cymer believes that it has sufficient working capital and available banking arrangements to sustain operations and provide for the future expansion of its business for at least the next
12 months.

At
September 30, 2001 and 2002, Cymer did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured
finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In
addition, Cymer did not engage in trading activities involving non-exchange traded contracts. As a result, Cymer is not exposed to any financing, liquidity, market or credit risk that
could arise if it had engaged in such relationships. Cymer does not have any relationships or transactions with persons or entities that derive benefits from their non-independent
relationship with the Company or its related parties except as disclosed herein.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Cymer's discussion and analysis of its financial condition and results of operations are based upon Cymer's consolidated financial statements, which have been
prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires Cymer to make estimates and use judgment
that may impact the reported amounts of assets, liabilities, revenues, expenses, and related disclosure of contingent assets and liabilities. As a part of its on-going internal processes,
Cymer evaluates its estimates, including those related to inventory reserves, warranty obligations, revenue recognition, allowances for bad debt, impaired assets, intangible assets, income taxes,
investments, and contingencies and litigation. Cymer bases these estimates upon both historical information and other assumptions that it believes valid and reasonable under the circumstances. These
assumptions form the basis for making judgments and determining the carrying values of assets and liabilities that are not apparent from other sources. Actual results could vary from those estimates
under different assumptions and conditions.

Cymer
believes that inventory allowances and warranty accruals require more significant judgments and estimates in the preparation of its consolidated financial statements than other
accounting policies.

Cymer
maintains an inventory allowance to record inventory at net realizable value. The value of this allowance is determined by taking into consideration certain assumptions related to
market conditions and future demands for its products which may result in excess or obsolete inventory. If actual market conditions are more or less favorable than projected by management, adjustments
to this inventory allowance may be required to more accurately value inventory.

20

---

Cymer
provides for the estimated cost of product warranties at the time the related revenue is recognized. The amount of this provision is determined by using a financial model which
takes into consideration actual historical expenses and potential risks associated with Cymer's different products. This financial model is then used to calculate the future probable expenses related
to warranty and the required level of the warranty provision. Although Cymer engages in product improvement programs and processes, its warranty obligation is affected by product failure rates and
costs incurred to correct those product failures at customer sites. Should actual product failure rates or estimated costs to repair those product failures differ from Cymer's estimates, revisions to
its estimated warranty provision would be required.

RECENT ACCOUNTING PRONOUNCEMENTS

In August 2001, the FASB issued Statement of Financial Accounting Standards No. 143 ("SFAS 143"), "Accounting for Asset Retirement
Obligations", which addresses financial accounting and reporting for
obligations associated with the retirement of tangible long-lived assets and for the associated asset retirement costs. SFAS 143 applies to tangible long-lived assets
that have a legal obligation associated with their retirement that results from the acquisition, construction or development or normal use of the asset. SFAS 143 requires that the fair value of
a liability for an asset retirement obligation be recognized in the period in which it is incurred if a reasonable estimate of fair value can be made. The fair value of the liability is added to the
carrying amount of the associated asset and this additional carrying amount is depreciated over the remaining life of the asset. The liability is accreted at the end of each period through charges to
operating expense. Cymer is required to adopt the provisions of SFAS 143 during the quarter ending March 31, 2003. It is not anticipated that the impact of this statement will have a
material effect on Cymer's consolidated financial statements.

In
April 2002, SFAS No. 145, "Rescission of FASB Statements No. 4, 44 and 64, Amendment of FASB Statement No. 13, and Technical Corrections"
("SFAS 145") was issued. SFAS 145 provides guidance on the classification of gains and losses from the extinguishment of debt and on the accounting for certain specified lease
transactions. This statement is effective for fiscal years beginning after May 15, 2002. It is not anticipated that the impact of this statement will have a material effect on Cymer's
consolidated financial statements.

In
July 2002, SFAS No. 146, "Accounting for Costs Associated with Exit or Disposal Activities" ("SFAS 146") was issued. SFAS 146 provides guidance on the
recognition and measurement of liabilities associated with exit and disposal activities. Under SFAS 146, liabilities for costs associated with exit or disposal activities should be recognized
when the liabilities are incurred and measured at fair value. This statement is effective prospectively for exit or disposal activities initiated after December 31, 2002. It is not anticipated
that the impact of this statement will have a material effect on Cymer's consolidated financial statements.

RISK FACTORS

In this section, references to "we", "us" or "our" are references to Cymer. Our business faces significant risks. The risks described
below may not be the only risks we face. Additional risks that we do not yet know of or that we currently think are immaterial may also impair our business operations. If any of the events or
circumstances described in the following risks actually occur, our business, financial condition or results of operations could suffer, and the trading price of our common stock could
decline.

21

---

Our revenues and operating results may fluctuate due to a variety of factors.

Our revenues and operating results from quarter-to-quarter may fluctuate significantly due to many factors including those listed in this
section and throughout this quarterly report on Form 10-Q for the period ending September 30, 2002. These factors include:



Also,
we have historically derived a large portion of our quarterly and annual revenues from selling a small number of light sources. Because we sell a small number of products, the
precise time that we recognize revenue from an order may have a significant impact on our total revenue for a particular period. Our customers may cancel or reschedule orders with little or no
penalty. Orders expected in one quarter could shift to another period due to changes in the anticipated timing of customers' purchase decisions or rescheduled delivery dates requested by our
customers. Our operating results for a particular quarter or year may be adversely affected if our customers cancel or reschedule orders, or if we cannot fill orders in time due to unexpected delays
in manufacturing, testing, shipping, and product acceptance.

We
manage our expense levels based, in large part, on expected future revenues. As a result, our expenses are relatively fixed for the short term, and if our actual revenue decreases
below the level we expect, our operating results will be adversely affected. As a result of these or other factors, we could fail to achieve our expectations as to future revenue, gross profit and
operating income. Our failure to meet the performance expectations set and published by external sources could result in a sudden and significant drop in the price of our stock, particularly on a
short-term basis, and could negatively affect the value of any investment in our stock.

Our business depends on the semiconductor equipment industry, which is volatile.

The semiconductor equipment industry is highly cyclical. We derive a substantial percentage of our revenues from photolithography tool manufacturers ("our
customers"). Our customers depend in turn on the demand for their photolithography tool products from their customers, the semiconductor device manufacturers. The capital equipment expenditures of
semiconductor manufacturers depend on the current and anticipated market demand for semiconductors and products using semiconductors.

22

---

The
semiconductor industry is cyclical in nature and historically has experienced periodic ups and downs and is currently in a significant downturn. This cyclical nature of the industry
in which we operate affects our ability to accurately predict future revenue and, thus future expense levels. When cyclical fluctuations result in lower than expected revenue levels, operating results
may be adversely affected and cost reduction measures may be necessary in order for us to remain competitive and financially sound. During a down cycle, we must be in a position to adjust our cost and
expense structure to prevailing market conditions and to continue to motivate and retain our key employees. In addition, during periods of rapid growth, we must be able to increase manufacturing
capacity and personnel to meet customer demand. We can provide no assurance that these objectives can be met in a timely manner in response to industry cycles.

The
current downturn has had a severe effect on the demand for semiconductor manufacturing equipment, including photolithography tools that our customers produce. We are not able to
predict when the semiconductor industry will recover. If overall market conditions continue to deteriorate in the near term, our current operating levels may negatively impact our profitability. We
believe that downturns in the semiconductor manufacturing industry will periodically occur, and result in periodic decreases in demand for all semiconductor manufacturing equipment, including
photolithography tools our customers manufacture. As a result, fluctuating levels of investment by semiconductor device manufacturers and pricing volatility will continue to materially affect our
aggregate bookings, revenues and operating results. Also, even during periods of reduced revenues we believe we must continue to invest in research and development and to maintain extensive ongoing
worldwide customer service and support capabilities to remain competitive, which may temporarily harm our financial results. Accordingly, these downturns are likely to continue to adversely affect our
business, financial condition and operating results and our operating results may fall below the expectations of public market analysts or investors in some future quarter or quarters. Such failure to
meet operating result expectations would materially adversely affect the price of our common stock.

Our
customers try to manage their inventories and production requirements to appropriate levels that best reflect their expected sales to semiconductor device manufacturers. Market
conditions in the industry and production efficiency of the photolithography tool manufacturers can cause our customers to expand or reduce their orders for new light source systems as they try to
manage their inventories and production requirements to these levels. We continue to work with our customers to better understand these issues. However, we cannot guarantee that we will be successful
in understanding our customers' inventory management and production requirements or that our customers will not build up an excess inventory of light source products. If our customers retain an excess
inventory of light source products, our revenue could be reduced in future periods as the excess inventory is utilized, which would adversely affect our operating results, financial condition and cash
flows.

We depend on the introduction of new products for our success, and we are subject to risks associated with rapid technological change.

Rapid technological changes in semiconductor manufacturing processes subject us to increased pressure to develop technological advances enabling such processes.
We believe that our future success depends in part upon our ability to develop, manufacture and timely introduce new light source products with improved capabilities and to continue to enhance our
existing light source systems and process capabilities. Due to the risks inherent in transitioning to new products, we must forecast accurate demand for new products while managing the transition from
older products.

Our
newest product introduction project consists of a technology change from a single- discharge-chamber designed excimer laser to a dual-discharge-chamber design called
MOPA. This MOPA design represents a paradigm shift from current lithography technology and is projected to enable higher power, tighter bandwidth and lower cost of operation for future optical
lithography applications across all three DUV wavelengths248nm, 193nm and 157nm. There are risks inherent in transitioning to this

23

---

new technology. These risks include timely and cost effective execution of the product development plan, adoption of the product by photolithography tool manufacturers and semiconductor
manufacturers, and the development of a comparable product by our competitors.

We
believe that semiconductor device manufacturers are currently developing a capability to produce devices that are measured at 0.13 micron or less, and these efforts are driving the
current demand for our light source products for DUV photolithography systems. After semiconductor device manufacturers have this capability, their demand for our light source products will depend on
whether they want to expand their capacity to manufacture these devices. This will in turn depend on whether their sales forecasts and projected manufacturing process yields justify the necessary
investments.

Future
technologies, such as EUV and scalpel processes, may render our excimer light source products obsolete. We must manage product transitions, as introduction of new products could
adversely affect our sales of existing products. If new products are not introduced on time, or have reliability or quality problems, our performance may be impacted by reduced orders, higher
manufacturing costs, delays in acceptance of and payment for new products, and additional service and warranty expenses. We may not be able to develop and introduce new products or enhancements to our
existing products and processes in a timely or cost effective manner that satisfies customer needs or achieves market acceptance. Failure to develop and introduce these new products and enhancements
could materially adversely affect our operating results, financial condition and cash flows.

We
expect to face significant competition from multiple current and future competitors. We believe that other companies are developing systems and products that are competitive to ours
and are planning to introduce new products to this market, which may affect our ability to sell our new products. Furthermore, new products represent significant investments of our resources and their
success, or lack thereof, could have a material effect on our financial results.

A significant percentage of our revenue is derived from sales to a few large customers, and if we are not able to retain these customers, or they reschedule, reduce or cancel
orders, our revenues would be reduced and our financial results would suffer.

Three large firms, ASM Lithography, Canon and Nikon dominate the photolithography tool business. Collectively, these three firms accounted for the following
percentage of our total revenue during the periods indicated:

Nine months ended
September 30,2001

2002ASM Lithography

29
%
34
%Canon

18

19Nikon

29

24Total

76
%
77
%


We
expect that sales of our light source products to these three customers will continue to account for a substantial majority of our revenue in the foreseeable future. None of our
customers are obligated to purchase a minimum number of our products. The loss of any significant business from or production problems for any one of these three customers will have a material adverse
effect on our business and financial condition. Sales to these customers may be affected by many factors, some of which are beyond our control. These factors include:



24

---



A substantial percentage of our revenue is derived from the sale of a limited number of primary products.

Our only product line is excimer laser light source systems, which include krypton fluoride, argon fluoride and fluorine systems, and we expect these primary
products to continue to account for a large percentage of our revenues in the near term. Continued market acceptance of our primary products is, therefore, critical to our future success. The primary
market for excimer laser light sources is in the use of DUV photolithography equipment for manufacturing deep-submicron semiconductor devices using smaller circuit geometries. The demand
for our products depends in part on the rate at which semiconductor device manufacturers further adopt excimer lasers as the chosen light source for their photolithography tools. Semiconductor
manufacturers may choose not to adopt excimer lasers for a variety of reasons, including:



We
cannot guarantee that these factors can or will be overcome or that the demand for our excimer laser light source products will not be materially reduced. The demand for our light
source products, and therefore our operating results, financial condition and cash flows, could be adversely affected by a number of factors, including:



We must effectively manage changes in our business.

In order to respond to the business cycles of the semiconductor industry, in the past few years we have sharply expanded and contracted the scope of our
operations and the number of employees in many of our departments. As the semiconductor industry grows and contracts we will need to:



If
we fail to effectively manage changes in our business, our operating results, financial condition and cash flows would be adversely affected.

25

---

We depend on a few key suppliers for purchasing components and subassemblies that are included in our products.

We purchase some of the components and subassemblies included in our light source products from a single supplier or a limited group of suppliers. For some of
these components and subassemblies, including specific optical components used in our light sources, there are no alternative sources of supply. In addition, we outsource the manufacture of various
subassemblies more often than in the past. Further, some of our suppliers have specialized in supplying equipment or manufacturing services to semiconductor equipment manufacturers and therefore have
been adversely affected by the current
industry downturn. If the current downturn continues for an extended period of time, these suppliers may not be able to continue to meet our requirements or respond quickly enough when the recovery
begins. Due to the nature of our product development requirements, these key suppliers must rapidly advance their own technologies and production capabilities in order to support the introduction
schedule of our new products. These suppliers may not be able to provide new modules and subassemblies when they are needed to satisfy our product schedule requirements. If we cannot purchase enough
of these materials, components or subassemblies, or if these items do not meet our quality standards, there could be delays or reductions in our product shipments, which would have a material adverse
effect on our operating results, financial condition and cash flows.

We face competition from two companies that have more resources available to them and may face competition from additional competitors who enter the market.

We are currently aware of two significant competitors that sell laser light source systems for DUV photolithography applications. These competitors are:



Both
of these companies:



We
believe that Gigaphoton and Lambda-Physik are aggressively trying to gain a larger market share in the excimer laser light source industry. We believe that our customers have
purchased products from these two competitors and that our customers have approved these competitors' laser light sources for use with their products. We believe that Gigaphoton, in particular, has
been approved by chipmakers in Japan and elsewhere for producing excimer laser light sources. Also, we believe that Lambda-Physik has been approved by chipmakers in the U.S. and Europe for producing
excimer laser light source products.

The
market for excimer laser light sources is still small and immature. Larger competitors with substantially greater resources, such as other manufacturers of industrial light sources
for advanced lithography, may attempt to sell competitive products to our customers. Potential competitors may also be attracted to our growing installed base of laser light sources and may attempt to
supply consumable products and refurbished parts to that installed base. If any existing or future competitors gain market acceptance we could lose market share and our growth could slow or decline,
which could have a material adverse effect on our operating results, financial condition and cash flows.

26

---

We depend on key personnel, especially management and technical personnel, who may be difficult to attract and retain in an expanding market.

We are highly dependent on the services of many key employees in various areas, including:



In
particular, there are a limited number of experts in excimer laser technology, and we require highly-skilled hardware and software engineers. Competition for qualified personnel is
intense and we cannot guarantee that we will be able to continue to attract and retain qualified personnel as needed. We have in the past experienced, and continue to experience, difficulty in hiring
personnel, including experts in excimer laser technology. We do not have employment agreements with most of our employees. We believe that our future growth and operating results will depend on:



If
we are unable to hire, train and retain key personnel as required, our operating results, financial condition and cash flows could be adversely affected.

Failure to maintain effectively our direct field service and support organization could have a material adverse effect on our business.

We believe it is critical for us to provide quick and responsive service directly to the semiconductor device manufacturers throughout the world that use our
light source products in their photolithography systems, and that it is essential to maintain our own personnel or trained third party resources to provide these services. Accordingly, we have an
ongoing effort to develop our direct support system with locations in the United States, Japan, Europe, Korea, Singapore, Taiwan and Southeast Asia. This requires us to do the following:



We
might not be able to attract and train qualified personnel to maintain our direct support operations successfully. Further, we may incur significant costs in providing these support
services. Failure to implement our direct support operation effectively could have a material adverse effect on our operating results, financial condition and cash flows.

Our ability to compete could be jeopardized if we are unable to protect our intellectual property rights. These types of claims could seriously harm our business or require us
to incur significant costs.

We believe our success and ability to compete depend in large part upon protecting our proprietary technology. We rely on a combination of patent, trade secret,
copyright and trademark laws,

27

---

non-disclosure and other contractual agreements and technical measures to protect our proprietary rights.

As
of September 30, 2002, we owned 158 United States patents covering certain aspects of technology related to excimer lasers and piezo techniques. These patents will expire at
various times during the period from January 2008 to September 2020. As of September 30, 2002, we also had applied for 92 additional patents in the United States. As of
September 30, 2002, we owned 141 foreign patents and had filed 333 patent applications pending in various foreign countries.

Our
pending patent applications and any future applications might not be approved. Our patents might not provide us with a competitive advantage and may be challenged by third parties.
In addition, third parties' patents might have an adverse effect on our ability to do business. As a result of cost constraints, we did not begin filing in Japan and other countries our patents for
inventions covered by United States patents and patent applications until 1993. As a result we lost the right to seek foreign patent protection for some of our early inventions. Additionally, laws of
some foreign countries in which our products are or may be developed, manufactured or sold, including various countries in Asia, may not protect our products or intellectual property rights to the
same extent as do the laws of the United States. Thus, the possibility of piracy of our technology and products are more likely in these countries. Further, third parties might independently develop
similar products, duplicate our products or, design around patents that are granted to us.

Other
companies or persons may have filed or may file in the future patent applications that are similar or identical to ours. We may have to participate in interference proceedings
declared by the United States Patent and Trademark Office ("USPTO") in order for the patent office to determine the priority of inventions. The patent office may determine that these third party
patent applications have priority over our patent applications. Loss of priority in these interference proceedings could result in substantial cost to us.

We
also rely on the following to protect our confidential information and our other intellectual property:



However,
we may not be successful in protecting our confidential information and intellectual property, particularly our trade secrets, because third parties may:



The parties to whom we provide research and development services may dispute the ownership of the intellectual property that we develop performing these services.

In the past, revenues from research and development arrangements with third parties have been used to pay for a portion of our own research and development
expenses. We receive these revenues from government sponsored programs, customers and from SEMATECH, a research consortium, in connection with our designing and developing specific products.
Currently, revenues from SEMATECH, photolithography tool manufacturers and semiconductor manufacturers are used to fund a small portion of our development expenses. In providing these research and
development services to these

28

---

manufacturers and SEMATECH, we try to make clear who owns the intellectual property that results from the research and development services we perform. However, disputes over the ownership or rights
to use or market this intellectual property may arise between us and the photolithography tool manufacturers and SEMATECH. Any dispute over ownership of the intellectual property we develop could
restrict our ability to market our products and have a material adverse effect on our business.

In the future, we may be subject to patent litigation to enforce patents issued to us and defend ourselves against claimed infringement by our competitors or any other third
party.

Third parties have notified us in the past, and may notify us in the future, that we are infringing their intellectual property rights. Also, we have notified
third parties in the past, and may notify them in the future, that they may be infringing our intellectual property rights.

Specifically,
Komatsu has notified us that we may be infringing some of its Japanese patents. During our discussions with Komatsu, they also asserted that we or our Japanese
manufacturing partner, Seiko, may be infringing on some of Komatsu's United States patents and a number of its additional Japanese patents. Komatsu has also notified one of our customers, Nikon, of
its belief that our laser light sources infringe several of Komatsu's Japanese and U.S. patents. As a result, we started proceedings in the Japanese Patent Office to oppose certain patents and patent
applications of Komatsu. The Japanese Patent Office has dismissed some of our opposition claims. Thus, litigation may result in connection with Komatsu's Japanese patents or U.S. patents. Also,
Komatsu might claim that we infringe other or additional patents. Komatsu notified Seiko, our manufacturing partner, that it intends to enforce its rights against Seiko with respect to its Japanese
patents if Seiko continues to engage in manufacturing activities for us. In connection with our manufacturing agreement with Seiko, we agree to pay Seiko under certain conditions for damages
associated with these types of claims. Seiko may not prevail in any litigation against Komatsu, and therefore, we may be required to pay Seiko for such damages.

We
have notified our competitors and others of our United States patent portfolio. Specifically, we have notified Komatsu that they may be infringing on some of our U.S. patents. We have
discussed with Komatsu our claims against each other. Komatsu challenged one of our U.S. patents in the USPTO. Also, Komatsu transferred its lithography laser business to one of our competitors,
Gigaphoton. We also have had discussions with Lambda-Physik, another competitor, regarding allegations by each party against the other for possible patent infringement. Any of these discussions with
our competitors may not be successful and litigation could result.

In
the future, patent litigation may result due to a claim of infringement by our competitors or any other third party or may be necessary to enforce patents issued to us. Any such
litigation could result in substantial cost and diversion of effort by us, which would have an adverse effect on our business, financial condition and operating results. Furthermore, our customers and
the end users of our products might assert other claims for indemnification that arise from infringement claims against them. If these assertions are successful, our business, financial condition and
operating results may be materially affected. Instead of litigation, we may seek a license from third parties to use their intellectual property. However, we may not be able to obtain a license on
reasonable terms. In the alternative, we may design around the third party's intellectual property right or we may challenge these claims in legal proceedings. Any adverse determination in a legal
proceeding could result in one or more of the following, any of which could have a substantial adverse effect on our business, financial condition and operating results:



29

---



Any
of these actions could be costly and would divert the efforts and attention of Cymer's management and technical personnel, which would materially adversely affect Cymer's business,
financial condition and results of operations.

Trademark infringement claims against our registered and unregistered trademarks would be expensive and we may have to stop using such trademarks and pay damages.

We registered the trademark "CYMER" in the United States and in some other countries. We are also trying to register additional trademarks in the United States in
other countries, including the trademark "Insist on Cymer." We use these trademarks and many other marks in our advertisements and other business materials, which are distributed throughout the world.
We may be subject to trademark infringement actions for using these marks and other marks on a worldwide basis and this would be costly to defend. If a trademark infringement action was successful, we
would have to stop using the mark and possibly pay damages.

If Seiko discontinues producing our laser light sources in Japan due to patent infringement claims made by Komatsu, our ability to meet the demand for our product in Japan
could be materially adversely affected.

We have approved Seiko as a qualified manufacturer of our excimer laser light sources. Komatsu has told Seiko that certain aspects of our laser light sources may
infringe Komatsu's Japanese patents. Further, Komatsu advised Seiko that it intends to enforce its rights under such Japanese patents against Seiko if Seiko continues to manufacture excimer laser
light source products for us. In connection with our manufacturing agreement with Seiko, we have agreed to indemnify Seiko against any such claims under certain circumstances. To date, Komatsu has not
initiated any such legal action. If Seiko stops manufacturing our laser light source products in Japan because of Komatsu's claims, our ability to manufacture laser light sources that are in demand in
such area could be materially and adversely affected.

Economic, political, regulatory and other events in geographic areas where we have significant sales or operations could interfere with our business.

A large portion of our total revenues is derived from customers located outside of the United States, particularly in Asian countries. We expect our international
sales to continue to account for a very large portion of our total revenues. In order to support our foreign customers, we must:



We
may not be able to manage our operations to address and support our foreign customers effectively. Further, our investments in these types of activities may not make us competitive in
the international market or we may not be able to meet the service and support levels required by our foreign customers.

Additionally,
we are subject to the risks inherent in doing business internationally, including:



30

---



Many
of our major customers and many of the semiconductor device manufacturers who use our laser light source products in their photolithography systems are located in Asia. Economic
problems and currency fluctuations affecting these regions in Asia could create a larger risk for us. Further, even though it has not been difficult for us to comply with United States export
controls, these export rules could change in the future and make it more difficult or impossible for us to export our products to many countries. Any of these vulnerabilities could have a material
adverse effect on our business, financial condition and results of operations.

We are dependent on air transport to conduct our business and disruption of domestic and international air transport systems could adversely affect our business.

We depend on regular and reliable air transportation on a worldwide basis for many of our routine business functions. If civil aviation in the United States or
abroad is disrupted by terrorist activities or
security responses to the threat of terrorism or for any other reason, our business could be adversely affected in the following ways:



We are exposed to risks related to the fluctuations in the currency exchange rates for the Japanese yen.

If we sell products to our Japanese subsidiary, the sale is denominated in U.S. dollars. If our Japanese subsidiary sells our products directly to customers in
Japan, the sale is denominated in Japanese yen. Thus, our results of operations may fluctuate based on the changing value of the Japanese yen to the U.S. dollar. Our Japanese subsidiary manages its
exposure to these fluctuations through foreign currency forward exchange contracts to hedge its purchase commitments. We will continue to monitor our exposure to these currency fluctuations, and, when
appropriate, use hedging transactions to minimize the effect of these currency fluctuations. However, exchange rate fluctuations may still have a material adverse effect on our operating results. In
the future, we may need to sell our products in other foreign currencies other than the Japanese yen and the management of more currency fluctuations will be more difficult and expose us to greater
risks in this area.

31

---

We are subject to many standards and regulations of foreign governments and, even though we intend to comply, we may not always be in compliance with these rules, or we may be
unable to design or redesign our products to comply with these rules.

Many foreign government standards and regulations apply to our products. These standards and regulations are always being amended. Although we intend to meet all
foreign standards and regulations, our products may not comply with these foreign government standards and regulations.
Further, it might not be cost effective for us to redesign our products to comply with these foreign government standards and regulations. Our inability to design or redesign products to comply with
foreign standards therefore could have a material adverse effect on our business.

Semiconductor device manufacturers' prolonged use of our products in high volume productions may not produce the results they desire and, as a result, our reputation and that
of our customers who supply photolithography tools to the semiconductor manufacturers could be damaged in the semiconductor industry.

Over time, our light source products may not meet semiconductor device manufacturers' production specifications or operating cost requirements after the light
source is used for a long period in high volume production. If any semiconductor device manufacturer cannot successfully achieve or sustain their volume production using our light sources, our
reputation could be damaged with the semiconductor device manufacturers and our customers who are the limited number of photolithography tool manufacturers. This would have a material adverse effect
on our business.

We have in the past and may in the future acquire business that will involve numerous risks. We may not be able to address these risks successfully without substantial expense,
delay or other operational and financial problems.

The risks involved with acquiring a new company include the following:



Any
of these risks could materially harm our business, financial condition and operating results. Further, any business that we acquire may not achieve anticipated revenues or operating
results.

Cymer Cambridge may not achieve the results we anticipate.

Cymer Cambridge's technology addresses stability and motion control challenges that we believe will be important to the future of the photolithography tool
industry. We purchased Cymer Cambridge with the expectation that the ACX technology would produce benefits to us, including:



32

---



We
cannot guarantee that we can effectively develop or market the ACX technology, that Cymer Cambridge can achieve anticipated results, or that the ACX technology will solve stability
and motion control challenges which are important to the future semiconductor market. Any of these risks could materially harm our business and condition and results of operations.

We must develop and manufacture enhancements to our existing products and introduce new products in order to continue to grow our business. We may not effectively manage our
growth and integrate these new enhancements and products, which could materially harm our business.

To continue to grow our business, our existing light source products and their process capabilities must be enhanced, and we must develop and manufacture new
products to serve other semiconductor applications. We cannot guarantee that we will be able to manage our growth effectively. Nor can we
guarantee that we will be able to accelerate the development of new enhancements to our existing products and create new products. Further, we may not be able to effectively integrate new products and
applications into our current operations. Any of these risks could materially harm our business, financial condition and results of operations.

We are dependent on our manufacturing facilities and subcontractors to assemble and test our products.

Operations at our primary manufacturing facility and our subcontractors are subject to disruption for a variety of reasons, including work stoppages, terrorism,
fire, earthquake, energy shortages, flooding or other natural disasters. Such disruptions could cause delays in shipments of our products to our customers. We cannot ensure that alternate production
capacity would be available if a major disruption were to occur or that, if it were available, it could be obtained on favorable terms. Such disruption could result in cancellation of orders or loss
of customers which have a material adverse effect on our operating results, financial condition and cash flows.

Our operations are subject to environmental and other government regulations that may expose us to liabilities for noncompliance.

We are subject to federal, state and local regulations, such as regulations related to the environment, land use, public utility utilization and the fire code, in
connection with the storage, handling, discharge and disposal of substances that we use in our manufacturing process and on our facilities that we lease. We believe that our activities comply with
current government regulations that are applicable to our operations and current facilities. We may be required to purchase additional capital equipment or other requirements for our processes to
comply with these government regulations in the future if they change. Further, these government regulations may restrict us from expanding our operations. Adopting measures to comply with changes in
the government regulations, our failure to comply with environmental and land use regulations, or restrictions on our ability to discharge hazardous substances, could subject us to future liability or
cause our manufacturing operations to be reduced or stopped.

Our products are subject to potential product liability claims if personal injury or death result.

We are exposed to significant risks for product liability claims if personal injury or death results from the use of our products. We may experience material
product liability losses in the future. We maintain insurance against product liability claims. However, our insurance coverage may not continue to be available on terms that we accept. This insurance
coverage also may not adequately cover liabilities that we incur. Further, if our products are defective, we may be required to recall or redesign these products. A successful claim against us that
exceeds our insurance coverage level, or any claim or

33

---

product recall that results in adverse publicity against us, could have a material adverse effect on our business, financial condition and results of operations.

The price of our common stock has fluctuated and may continue to fluctuate widely.

The price of our common stock has fluctuated in the past. The market price of our common stock will continue to be subject to significant fluctuations in the
future in response to a variety of factors, including the risk factors contained in this report.

Various
factors may significantly affect the market price of our common stock, including:



In
addition, the stock market has experienced extreme price and volume fluctuations that have particularly affected the market price for many high technology companies. Such fluctuations
have in some cases been unrelated to the operating performance of these companies. Severe price fluctuations in a company's stock have frequently been followed by securities litigation. Any such
litigation can result in substantial costs and a diversion of management's attention and resources and therefore could have a material adverse effect on Cymer's business, financial condition and
results of operations.

We have implemented steps to protect our company from hostile takeovers.

Nevada law and our articles of incorporation contain provisions that discourage a proxy contest and provisions that make an acquisition of a substantial block of
our common stock more difficult. In addition, our board of directors is authorized to issue, without stockholder approval, shares of preferred stock. Such shares of preferred stock may have voting,
conversion and other rights and preferences that may be superior to those of the common stock and this could adversely affect the voting power or other rights of holders of common stock. Our board can
use the issuance of the preferred stock or rights to purchase the preferred stock to discourage any unsolicited acquisition proposal or attempt.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

Foreign Currency Risk

Cymer conducts business in several international currencies through its worldwide operations. Due to the large volume of Cymer's business that is conducted in
Japan, the Japanese operation poses the greatest foreign currency risk. Cymer uses financial instruments, principally foreign currency forward exchange contracts, in Japan to manage its foreign
currency exposures. Cymer enters into foreign currency forward exchange contracts in order to reduce the impact of currency fluctuations related to purchases of Cymer's inventories by Cymer Japan in
US dollars for resale under firm third-party sales

34

---

commitments denominated in Japanese Yen. Cymer does not enter into foreign currency forward exchange contracts for trading purposes.

As
of September 30, 2002, Cymer had outstanding foreign currency forward exchange contracts to buy US $59.0 million for 7.3 billion yen under foreign currency
exchange facilities with contract rates ranging from 115.50 yen to 133.02 yen per U.S. dollar. These contracts expire on various dates through July 2003.

Investment and Debt Risk

Cymer maintains an investment portfolio consisting primarily of government and corporate fixed income securities, certificates of deposit and commercial paper.
While it is Cymer's general intent to hold such securities until maturity, Cymer will occasionally sell certain securities for cash flow purposes. Therefore, Cymer's investments are classified as
available-for-sale and are carried on the balance sheet at fair value. Due to the conservative nature of the investment portfolio, a sudden change in interest rates would not
have a material effect on the value of the portfolio.

In
February 2002, Cymer issued $250 million in aggregate principal amount in a second private placement of notes. The notes are unsecured and are due on February 15,
2009 with interest payable semi-annually on February 15 and August 15 of each year at a fixed interest rate of 31/2% per annum. The notes are convertible into
shares of Cymer common stock at a conversion rate of 20 shares per $1,000 principal amount. Cymer used a portion of the net proceeds from this private placement to redeem the notes issued in
August 1997. These notes are recorded at face value on the consolidated balance sheets. The fair value of such debt based on quoted market prices on September 30, 2002 was
$196.3 million.

ITEM 4. Controls and Procedures

Evaluation of disclosure controls and procedures.Cymer's chief executive officer and its chief financial officer,
after evaluating the effectiveness of Cymer's disclosure controls and procedures (as defined in Exchange Act Rule 13a-14) as of a date within 90 days of the filing date of
this quarterly report on Form 10-Q (the "Evaluation Date"), have concluded that as of such date, Cymer's disclosure controls and procedures were adequate and sufficient to ensure
that information required to be disclosed by Cymer in the reports that it files under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time period
specified in the Commission's rules and forms.

Changes in internal controls.There have been no significant changes in Cymer's internal controls since the Evaluation Date. Cymer is not
aware of any significant change in any other factor that could significantly affect its internal controls subsequent to the Evaluation Date.

35

---



PART II. OTHER INFORMATION

ITEM 1. Legal Proceedings

None.

ITEM 2. Changes in Securities and Use of Proceeds

None.

ITEM 3. Defaults upon Senior Securities

None.

ITEM 4. Submission of Matters to a Vote of Security Holders

None.

ITEM 5. Other Information



ITEM 6. (a) Exhibits





36

---



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this quarterly report on Form 10-Q to be
signed on its behalf by the undersigned thereunto duly authorized.

|                        |  | CYMER, INC.
(Registrant)
|----------------------- |  | ------------------------
|Date: November 12, 2002 |  | By:                     

37

---



CERTIFICATION

I,
Robert P. Akins, certify that:

1.    I
have reviewed this quarterly report on Form 10-Q of Cymer, Inc.;

2.    Based
on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.    Based
on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4.    The
registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-14 and 15d-14) for the registrant and we have:



5.    The
registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's
board of directors (or persons performing the equivalent function):



6.    The
registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other
factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material
weaknesses.

|Date: November 12, 2002 |  |                                                                     |  | 
|----------------------- |  | ------------------------------------------------------------------- |  | 
|                        |  | /s/ROBERT P. AKINSRobert P. Akins Chairman, Chief Executive Officer |  | 

38

---

CERTIFICATION

I,
Nancy J. Baker, certify that:

1.    I
have reviewed this quarterly report on Form 10-Q of Cymer, Inc.;

2.    Based
on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.    Based
on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4.    The
registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-14 and 15d-14) for the registrant and we have:



5.    The
registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's
board of directors (or persons performing the equivalent function):



6.    The
registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other
factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material
weaknesses.

|Date: November 12, 2002 |  |                                                                             |  | 
|----------------------- |  | --------------------------------------------------------------------------- |  | 
|                        |  | /s/NANCY J. BAKERNancy J. Baker Sr. Vice President,
Chief Financial Officer |  | 

39

---

QuickLinks